Dr. Vincent Bond is an HIV/AIDS researcher, presenting his work at numerous national as well as international HIV meetings. He has served as ad hoc reviewer for several leading virological journals and has authored/co-authored over 125 scientific communications. These communications include: abstracts, six patent applications, two granted patents, and 45 publications, 31 of which are articles in peer-reviewed journals focused on aspects of HIV pathogenesis research. He received his B.S., M.S., and Ph.D. at the Pennsylvania State University in Viral Genetics, and subsequently, did a postdoctoral fellowship at the California Institute of Technology (Caltech). There he extended his knowledge of host systems through the study of basic cell biology processes. Simultaneously, the basic life processes of the Human Immunodeficiency Virus I (HIV-1) were being elucidated elsewhere. Interesting commonalities between his cell work at Caltech, and aspects of HIV biology, enticed him, on arriving at the Morehouse School of Medicine in 1990, to begin to look at host-HIV-1 interactions and the role, if any, this plays in progression to AIDS. Currently, a Professor of Microbiology, Biochemistry, and Immunology, he has studied HIV/AIDS for 20 years and is an expert in HIV pathogenesis. His lab has focused its efforts on understanding the role(s) played by HIV-1 accessory proteins in the pathogenic manipulation of host systems. Over the last decade his lab has focused on the role of extracellular Nef-containing exosomes in HIV/SIV infection and pathogenesis leading to AIDS. Publications arising out of grant funded research have shown that the Nef protein is released from viral-infected cells in exosomal vesicles that can induce apoptosis, or can cause gene dysregulation in bystander cells leading to immune depletion/dysfunction capable of causing the pathogenesis leading to AIDS. This work has the potential to lead to newly identified targets for AIDS therapy and a potential therapeutic antagonist. It also has therapeutic ramifications for cancer therapy.